REFERENCES
- Sax PE, DeJesus E, Mills A, et al. Co-formulated elvite-gravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012; 379: 2439–2448.
- DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir diso-proxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fuma-rate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012; 379: 2429–2438.
- Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobici-stat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treat-ment-naive HIV type 1-infected patients: Week 48 results. J Infect Dis. 2013;208:32–39.
- Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145: 247–254.
- Levey AS, Stevens LA, Schmid CH, et al. A new equa-tion to estimate glomerular filtration rate. Ann Intern Med. 2009;150: 604–612.
- Stevens LA, Levey AS. Current status and future perspec-tives for CKD testing. Am J Kidney Dis. 2009;53:S17–26.
- German P. Pharmacokinetics of elvitegravir and cobicistat in subjects with severe renal impairment. Presented at 13th International Workshop on Clinical Pharmacology of HIV Therapy; April 16–18, 2012; Barcelona, Spain. Poster 38.